Literature DB >> 6326791

Alpha 1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer.

L Sparos, Y Tountas, C Chapuis-Cellier, G Theodoropoulos, D Trichopoulos.   

Abstract

Serum levels of alpha 1-antitrypsin (alpha 1 AT) were measured by radial immunodiffusion and phenotypes were determined by electrofocusing in acrylamide gel in 39 patients with hepatocellular carcinoma (HCC) positive for serum hepatitis B surface antigen (HBsAg), 41 patients with HCC negative for serum HBsAg, and 160 age- and sex-matched hospital controls. There was no difference between the control series and either of the two HCC groups with respect to alpha 1 AT phenotype pattern; also, there was no evidence of association between HCC and either the M2 allele or any of the alpha 1 AT deficiency phenotypes. However, HCC cases negative for HBsAg had significantly higher serum alpha 1 AT values (mean 665 +/- 26 mg 100 ml-1) than HCC cases positive for HBsAg (mean 571 +/- 23 mg 100 ml-1), who in turn, had significantly higher alpha 1 AT values than hospital controls (mean 434 +/- 13 mg 100 ml-1). These results indicate that in Greece, as in other high HCC incidence countries, genetically determined alpha 1 AT deficiency is not aetiologically important; the increase of serum alpha 1 AT is an important correlate of HCC with possible aetiologic significance and diagnostic potential and HBsAg-positive HCC and HBsAg-negative HCC are manifest differently as well as being aetiologically distinct.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326791      PMCID: PMC1976722          DOI: 10.1038/bjc.1984.90

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Preferential transmission of the Z deficient allele of alpha 1-antitrypsin.

Authors:  C Chapuis-Cellier; P Arnaud
Journal:  Science       Date:  1979-07-27       Impact factor: 47.728

2.  Expression of protein markers in malignant hepatoma: evidence for genetic and epigenetic mechanisms.

Authors:  P E Palmer; A A Ucci; H J Wolfe
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

Review 3.  [Alpha 1-antitrypsin deficiency and the liver (author's transl)].

Authors:  H J Spech; H Liehr
Journal:  Z Gastroenterol       Date:  1982-07       Impact factor: 2.000

4.  Protease inhibitors--a precarious balance.

Authors:  P C Harpel
Journal:  N Engl J Med       Date:  1983-09-22       Impact factor: 91.245

5.  Hepatitis B virus and cigarette smoking: risk factors for hepatocellular carcinoma in Hong Kong.

Authors:  K C Lam; M C Yu; J W Leung; B E Henderson
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Does hepatitis B virus cause hepatocellular carcinoma?

Authors:  D Trichopoulos; J Kremastinou; A Tzonou
Journal:  IARC Sci Publ       Date:  1982

Review 7.  The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease.

Authors:  H L Sharp
Journal:  Gastroenterology       Date:  1976-04       Impact factor: 22.682

8.  A clinical evaluation of serum alpha-1-antichymotrypsin levels in liver disease and cancers.

Authors:  S Matsuzaki; K Iwamura; M Itakura; H Kamiguchi; T Katsunuma
Journal:  Gastroenterol Jpn       Date:  1981-12

9.  Smoking and hepatitis B-negative primary hepatocellular carcinoma.

Authors:  D Trichopoulos; B MacMahon; L Sparros; G Merikas
Journal:  J Natl Cancer Inst       Date:  1980-07       Impact factor: 13.506

10.  M2 alpha-1-antitrypsin phenotype and primary liver cancer.

Authors:  P Sizaret; M Clerc; J Estève; R R Frants; J Pillot
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

View more
  2 in total

Review 1.  Alpha 1-antitrypsin deficiency and liver disease.

Authors:  P Birrer; N G McElvaney; L M Chang-Stroman; R G Crystal
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

2.  Alpha 1-antitrypsin and survival in hepatocellular carcinoma.

Authors:  A Tzonou; L Sparos; V Kalapothaki; X Zavitsanos; A Rebelakos; D Trichopoulos
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.